Conditions: Non-small Cell Lung Cancer Metastatic
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 642
Healthy volunteers: no

Brief summary:
The purpose of this research study is to compare the effectiveness and safety of ABP 215 against bevacizumab in men and women with advanced non-small cell lung cancer.

Detailed description:

Arms:
arm 1: Participants received 15 mg/kg ABP 215 administered as an intravenous (IV) infusion every 3 weeks (Q3W) for 6 cycles and carboplatin and paclitaxel chemotherapy Q3W for at least 4 and not more than 6 cycles. arm 2: Participants received bevacizumab 15 mg/kg administered as an intravenous (IV) infusion every 3 weeks (Q3W) for 6 cycles and carboplatin and paclitaxel chemotherapy Q3W for at least 4 and not more than 6 cycles.

Interventions: intervention 1: Carboplatin intervention 2: Paclitaxel intervention 3: ABP 215 intervention 4: Bevacizumab
Intervention descriptions: intervention 1: Administered at an area under the concentration-time curve (AUC) 6 by IV infusion Q3W intervention 2: Administered 200 mg/m² IV Q3W intervention 3: Administered 15 mg/kg Q3W by IV infusion intervention 4: Administered 15 mg/kg Q3W by IV infusion

Protocol document: